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What we knew
 Hypogonadism is increasingly being recognised as relevant to overall male health.
 However the rate of identification and treatment of hypogonadism even in 
developed health care economies remains low as as evidenced by Klinefelter 
Syndrome which affects approximately one in every 660 men but only 25% of the 
expected number of men are diagnosed with this condition, and of these only a 
minority are diagnosed before puberty.
 There are two main treatment options - injections or gels and these are used at 
various dose levels.
What we have learnt
 The largest volume (by prescribing amount) agents were injectable preparations at 
a total cost in 2018/19 of £8,172,519, with the gel preparations in second place at 
a total cost of £4,795,057. Transdermal patches, once the only alternative to 
testosterone injections or implants were little prescribed with the national annual 
cost being £222,022.
 There was a strong relation between PDE5-I prescribing and testosterone 
prescribing. Other factors independently linked with more testosterone prescribing 
were: HIGHER proportion of men with type 2 diabetes (T2DM) on target control 
and HIGHER overall practice rating on the National Patient Survey for ‘good 
experience’, while non-white ethnicity and socio-economic deprivation were 
associated with less testosterone prescribing. A number of comorbidity factors 
associated with less prescribing of testosterone (such as hypertension, T2DM and 
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 The variation between general practices in prescribing of testosterone in a well 
organised developed health economy, is only related in a small degree (r2=0.27) 
including 19 factors all with p values <0.05 to factors that we can define, as there 
is presently no universally accepted national guidance for the UK.
Abstract
Introduction
We have previously reported rates of diagnosis of male hypogonadism in United 
Kingdom (UK) general practices. We aimed to identify factors associated with 
testosterone prescribing in UK general practice.
Methods
We determined for 6741 general practices in England, the level of testosterone 
prescribing in men and the relation between volume of testosterone prescribing and 1) 
demographic characteristics of the practice 2) % patients with specific comorbidities 3) 
national GP patient survey results.  
Results
The largest volume (by prescribing volume) agents were injectable preparations at a total 
cost in the 12-month period 2018/19 of £8,172,519 with gel preparations in second place: 
total cost £4,795,057. Transdermal patches, once the only alternative to testosterone 
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The analysis accounted for 0.27 of the variance in testosterone prescribing between 
general practices. Thus most of this variance was not accounted for by the analysis. 
There was a strong univariant relation (r=0.95, p<0.001) between PDE5-I prescribing and 
testosterone prescribing. Other multivariant factors independently linked with more 
testosterone prescribing were: HIGHER proportion of men with type 2 diabetes(T2DM) on 
target control (HbA1c ≤58 mmol/mol) and HIGHER overall practice rating on the National 
Patient Survey for good experience, while non-white ethnicity and socio-economic 
deprivation were associated with less testosterone prescribing. There were a number of 
comorbidity factors associated with less prescribing of testosterone (such as T2DM, 
hypertension and stroke/TIA).
Conclusion
Our analysis has indicated that variation between general practices in testosterone 
prescribing in a well developed health economy, is only related in small degree (r2=0.27) 
to factors that we can define. This suggests that variation in amount of testosterone 
prescribed is largely related to general practitioner choice/other factors not studied and 
may be amenable to measures to increase knowledge/awareness of male 
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Introduction
Hypogonadism (HG) in men has been associated with loss of sexual function, increased 
frailty and other co-morbidities including increased mortality (1).  Hypogonadism itself is 
broadly referred to as testicular failure associated with androgen deficiency (2) although 
such a broad definition encompasses many men and has required sub-classification 
based on cause and age (3). The precise cut points on the basis of morning testosterone 
levels vary across guidance documents both within and between areas of the world 
(4,5,6,7). Moreover, reference ranges quoted by UK laboratories are not commonly 
derived from fasting samples only or from samples taken in the morning (<11:00 am) and 
are usually manufacturer derived (50%) or historical (18.8%) (8).
The rate of identification and treatment of hypogonadism even in developed health care 
economies remains low as evidenced by Klinefelter Syndrome which affects 
approximately one in every 660 men but only 25% of the expected number of men are 
diagnosed with this condition, and of these only a minority are diagnosed before puberty 
(9).
Testosterone is implicated in regulating metabolic functions, maintenance of muscle and 
bone, and inhibition of adipogenesis. In older individuals, reduced testosterone is 
associated with sarcopenia and sarcopenic obesity (4). Men with primary frailty, or 
primary obesity will necessarily exhibit lower testosterone levels as a normal 
physiological response. Several international guidelines recommend that all men with 
erectile dysfunction (ED), type 2 diabetes (T2DM), metabolic syndrome, and obesity (BMI 
>30 kg/m2) should be routinely screened for HG (10,11,12) with ED and HG now 
recognised as independent risk factors for cardiovascular disease.(12,13) However the 
two Endocrine societies to have hitherto issued published guidance do not recommend 
routine screening in men with obesity, diabetes, or metabolic syndrome in the absence of 
other risk factors or clinical features (14,15) 
The rate of identification and treatment of HG in the developed health care economies of 
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there is an “epidemic” of testosterone prescribing, prompting lively debate in the 
literature. There are two main treatment options - injections or gels and these are used at 
various dose levels (injections can also be used at different frequencies) (6,7). The 
treatment of HG often goes in tandem with treatment of ED with phosphodiesterase type 
5-inhibitors (PDE5-Is) (17) which are shown to be of benefit for reducing cardiovascular 
risk in T2DM (17,18,19).
We previously reported rates of diagnosis of male hypogonadism in United Kingdom (UK) 
general practices (16). The reasons for the possible under treatment of hypogonadism in 
UK general practice are multiple. In order to gain a greater understanding of this, we here 
describe what are the determinants of testosterone prescribing at general practice level 
and the changes year on year in the balance of treatments used to treat male HG, while 
also analysing the changes year on year in testosterone prescribing overall. 
Methods
We analysed data for general practices in England over the operational years 2011/12 to 
2018/19, with a focus in detail on the final year 2018/19 (current year at the time of 
writing) as representative of prescribing practice. 
We determined for each of 6741 general practices in England in 2018/19, the prescribing 
at a practice level of testosterone as described in Table 1.
Data Sources
Details about the location of each practice were obtained from the Office for National 
Statistics (ONS). General Practice Workforce Survey (20) provides details on the general 
practitioners in each practice and the following indicators were used. The Quality 
Outcomes Framework (QOF) (21) is the system that provides incentives to family doctor 
practices in the UK to manage a number of long term conditions. Each practice maintains 
registers of patients with specific conditions the % of total population was used for the 
following conditions. The National Diabetes Audit (22) provided information on the 
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Primary care prescribing data (24) was downloaded and assembled including the British 
National Formulary (BNF) code, quantity, items and costs of all prescriptions. This was 
linked to the Defined daily Dose (DDD), taken from the WHO ATC which is the assumed 
average maintenance dose per day for a drug used for its main indication in adults and is 
a widely used metric (24). Prescribing rates were adjusted according to DDD principles.  
The DDD is a statistical measure of drug consumption, defined by the World Health 
Organization Collaborating Centre for Drug Statistics Methodology. 
Testosterone
 Number of different HG treatment applied (Number of different Testosterone 
medications used within the practice by method and dose)
 Testosterone % Injected (% of total Testosterone DDD)
 Testosterone Gel % dispensed by pumps (% of total Gel DDD)
PDE5-I
 Use of oral PDE5-I was calculated Annual Quantity prescribed as a ratio to males 
age >40 years
 Dose Level of PDE5-I was calculated from total DDD PDE5-I/Total Quantity of 
PDE5-I tablets
Details of these are given in Table  2. 
Descriptive analysis
The actual number being treated within each practice was defined by the amount of 
testosterone being prescribed converted to the DDD (24), which is the assumed average 
maintenance dose per day for a drug used for its main indication in adults and is a widely 
used metric (24). WHO ATC values mg/DDD for testosterone parenterally, transdermally 
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The percentage expected hypogonadal patients for each practice were estimated from 
the expected prevalence by age group for Europeans by the European Male Ageing 
(EMAS) Study (3). The EMAS Study recruited 396/3369 (11.75%) of men from England. 
To examine the link between use of PDE5-Is and testosterone, the use of testosterone 
was calculated by dividing the total actual amount in annualised DDD by the expected 
number of symptomatic HG patients calculated from linking the age prevalence given by 
Wu et al (3) with numbers of males by age group in each practice to give an overall % 
identified and treated. The % using PDE5-I was calculated by dividing the total quantity of 
tablets prescribed, by the number of male population age >40 and 52 (as NHS only 
allows prescription of 1 PDE5I tablet/week). The practices were then broken up into 
deciles of both PDE5-I and testosterone use. We did not have data concerning 
testosterone prescription for primary vs secondary hypgonadism. 
Statistics
Multivariate backward stepwise linear regression analysis weighted by the population 
males aged >40 years was conducted to examine which factors independently linked with 
% of testosterone prescribing (dependent variable) at general practice level. The 
independent variables are described in Table 1. All of these are continuous except for 
number of testosterone preparations which is ordinal. A p value of <0.05 was taken as 
the cut point to consider as significant. We had in our full original assessment 25 factors 
that considered wide range of possible influences. We retained only those factors that 
kept a p-value <0.05. In the end 19 factors remained significant.
Practices finally included in the analysis had:
a) data for all the required fields
b) ≥500 total male population
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All of the data that we used for the analysis is publically available. No patient level data 
was utilised for the analysis. 
Results
Volume and cost of testosterone prescribing
The prescribing of testosterone for 6741 UK General Practices is shown in Table 2. The 
largest volume (by prescribing amount) agents were injectable preparations at a total cost 
in 2018/19 of £8,172,519, with the gel preparations in second place at a total cost of 
£4,795,057. Transdermal patches, once the only alternative to testosterone injections or 
implants were little prescribed with the national annual cost being £222,022. There were 
some testosterone tablets and implants used but in low volume accounting for £36,502 of 
costs annually (<0.5% of total). 
The overall average cost/day of testosterone replacement in its entirety was £1.23.
Variation in prescribing 
Data from 6,741 general practices were examined. There was great variation in practices 
in use of testosterone injections. While the mean was 63% of testosterone doses are 
given by injection, there were over 10% of practices who gave 100% by injection and 
over 10% who gave 0% as injection. The majority of the rest of the testosterone 
replacement was given as testosterone gel. 
Change in testosterone prescribing year on year 2011 to 2018 (Figure 1)
The overall use of testosterone grew 45% from an average of 31,000 to 44,800 DDD/day 
over the years 2011 to 2018, with injectable preparations growing by 84% and 
transdermal preparations by 25%. The transdermal preparations have has moved from 
93% in portion, sachets and tubes to now 76% by pump. Oral testosterone capsules have 
fallen from 5% to 0.9%.
How testosterone prescribing relates to possible need (Figures 2 and 3)
In Figure 2, we have shown for all the 6741 general practices included in the survey, the 
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(DDD) and predicted prevalence of HG at the same general practice. This is plotted with 
each practice shown as a single point in Figure 3. The expected number of hypogonadal 
men in each practice is shown on the x-axis of Figure 3. The majority of practices 
prescribe no more than 20% of the predicted amount of testosterone that may be 
required on the basis of the number of men predicted to have a degree of HG. Only the 
practices with a lower expected prevalence of HG achieved even one third of the 
predicted need for testosterone
Relation of testosterone prescribing to PDE5-I prescribing at general practice level 
(Figure 4)
The prescribing of testosterone did relate closely to PDE5-I prescribing in univariate 
analysis (Figure 4) with r2=0.89.  There was a much greater variation across the general 
practices in testosterone prescribing compared with PDE5-I prescribing when compared 
with the median for the general practices (Figure 4) and as described next. For 
testosterone supplements, the lowest decile of prescribing categories was 30% of the 
median vs 250% of the median for the top decile = more than 8 fold difference; vs 
PDE5-is, where the lowest decile was 60% of the median vs 150% of the median for the 
top decile = 2.5 times difference between the lowest and highest decile. 
Factors related to testosterone prescribing in multiple regression analysis (Figure 
5)
The variance accounted for by the analysis, r2 = 0.27, so much of the variance was not 
accounted for by the analysis of nationally available metrics as detailed as these are. 
a) Prescribing behaviour of PDE5-is influenced the levels
b) General practice workforce (age, gender and country of qualification (COQ) of the 
general practitioner had little influence)
c) Poor local health reduced the level
d) Older age of men in the practice reduced the level
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f) Practices with a higher proportion of type 2 diabetes (T2DM) patients with good 
glycaemic control, prescribed more testosterone
There was a strong relation between PDE5-I prescribing and testosterone prescribing 
(p<0.001) for general practices.  The analysis showed that the other factors 
independently linked with more testosterone prescribing were: HIGHER proportion of 
men with T2DM on target control (p<0.001) and HIGHER overall practice rating on the 
National Patient Survey (17) (for good experience (p=0.008) while non-white ethnicity 
(black and minority ethnicity (BAME)) (p<0.001) and income deprivation (p<0.001) were 
associated with less testosterone prescribing. 
There were many comorbidity factors associated with greater prescribing of testosterone, 
specifically COPD and some comorbidity factors related to less prescribing of 
testosterone, specifically the proportion of individuals over 40 years old with T2DM in the 
practice (p<0.001) and more people on the hypertension and stroke/ transient ischaemic 
attack registers. 
In relation to the characteristics of the general practice, practices with a higher proportion 
of younger general practioners tended to prescribe less testosterone as did general 
practices in the south vs the north of England, defined by their latitude. 
Discussion
We found a strong relation (r=0.21, p<0.001) between PDE5-I prescribing and 
testosterone prescribing, which suggests that willingness to prescribe these agents to 
some degree may to some degree go hand in hand. Other factors independently linked 
with more testosterone prescribing were: HIGHER proportion of men with type 2 diabetes 
(T2DM) on target control (HbA1c ≤58 mmol/mol) and HIGHER overall practice rating on 
the National Patient Survey for good experience, while non-white ethnicity and socio-
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number of comorbidity factors associated with less prescribing of testosterone, such as 
T2DM and stroke/TIA.
The variation between general practices in prescribing of testosterone in a well organised 
developed health economy, is only related in a small degree,  including 19 factors all with 
p values <0.05 to factors that we can define, implying that most prescribing is determined 
by doctor preference rather than any national guidance. 
Restandol was prescribed but in low volume accounting for £113,074 of costs annually 
(<0.5% of total). Given that Restandol is ineffective as a testosterone replacement unless 
taken with a high fat meal, it is puzzling that it is still being prescribed in 267 practices. 
This may be because for a minority of men Restandol is the only form of testosterone 
replacement that they can tolerate. 
Testosterone prescribing vs possible prevalence of hypogonadism – what can we 
do about this?
Figures 2 and 3 show the proportion of testosterone prescribed vs projected need.  In 
relation to the novelty of our work, we accept that there is no register at a general 
practice level of men with hypogonadism. However we feel that the projections that we 
have made, are plausible. It should be pointed out that nay projections based on the 
EMAS findings (3,16) will always exceed the prevalence in NHS practice since there is a 
threshold (of unknown magnitude) which stops men with symptoms from seeking medical 
advice from their GP.
Although there is no justification for withholding testosterone treatment from older men 
with verified hypogonadism, there remain major concerns about the safety and benefit of 
prescribing testosterone to those older men whose low testosterone levels instead may 










This article is protected by copyright. All rights reserved
Discrepancies among the several available guidelines do not help to clarify the scenario 
(5). The debate on who should receive testosterone supplementation continues in the 
literature and elsewhere (26). 
In fact only the practices with a lower expected prevalence of hypogonadism achieved 
even a third of the need for testosterone that we would predict from our modelling. 
Greater awareness of the importance of screening for hypogonadism and clear 
discussion support from the local hospital laboratories may help to address this as will 
awareness of the risks of leaving hypogonadism untreated (27,28). A recent paper 
pointed to a real risk of over diagnosis and unnecessary treatment with testosterone. It 
was pointed out that suboptimal sampling conditions can lead to misinterpretation of 
serum biochemistry with men not having verified as having hypogonadism being starged 
on therapy (26). 
Nevertheless we feel that the differences that we report between general practices and 
potential determinants of the differences in testosterone prescribing at a general practice 
level are important findings. Unless there is a strong clinical context (e.g. a pubertal male 
with small testes) or raised LH level indicating organic testicular failure, at least 2 fasted 
early morning samples for serum testosterone should be taken (6,7,8), with addition of 
SHBG if necessary - in order to estimate circulating free testosterone (27) - before a 
diagnosis of hypogonadism is made.
  
 
Why is there such a difference between general practices in testosterone 
prescribing?
Our analysis has indicated that the variation between general practices in prescribing of 
testosterone in a well organised developed health economy, is only related in a small 
degree (r2=0.27) to factors that we can define (Figure 5). This suggests that the variation 
in the amount of testosterone prescribed at a general practice level (adjusted for the 
number and proportion of older men) is largely related to the general practitioner choice / 
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to measures to increase knowledge and awareness (5,16, 27,28) with a view to 
prescribing testosterone where appropriate. 
Testosterone prescribing and awareness of sexual health
There was a strong univariate correlation between testosterone and PDE5-I prescribing 
at a GP practice level (Figure 4). This is not surprising as current expert guidelines 
recommend testosterone measurement for all men presenting with ED as well as 
screening all men with T2DM for low testosterone (3,4,5,6). It should be pointed out that 
in the case of men with T2DM, there are usually multifactorial causes of their ED, 
including vascular disease.
Unfortunately, there is no current guidance from NICE (the National Institute for Health 
and Care Excellence), the major organisation for change in UK practice. Over 7 years 
2011 to 2018 there was increase overall in testosterone prescribing in England with an 
increase in the proportion of gel (increasingly gel delivered by pump) prescribed. 
We found that the highest prescribing practices were prescribing 4 times as much PDE5-I 
and 2 times as much testosterone as the lowest prescribing practices for older men. This 
implies that the higher testosterone prescribing practices may have a greater awareness 
of male sexual health. Where appropriate testosterone supplementation and PDE5-I 
therapy, as we and others previously have shown, are associated with significantly 
reduced mortality and cardiovascular morbidity in men with T2DM (17,18,19,28). Further 
work is required in this area in relation to a dedicated randomised controlled trial (RCT) of 
PDE5-I therapy being conducted. 
Prescribing patterns
The continued prescribing of oral preparations, such as Restandol in a few GP practices 
appears inappropriate as injections and gels show greater efficacy and fewer adverse 
events (7). The predominance of depot testosterone injection is indicative of the 
convenience of this mode of administration, although the market share of the gel 
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The unknowns
In multivariate analysis, good glycaemic control and good patient experience of their 
general practice were positively associated with testosterone prescribing while 
economic deprivation and high proportion non-white (BME) ethnicity were negatively 
associated. The relation between testosterone prescribing and comorbidities was 
complex as described in the results section and shown in Figure 5. A greater number of 
men over 40 with T2DM in a general practice, was associated strongly with less 
testosterone prescribing,. These findings merit further exploration beyond the scope of 
this paper. 
In fact most of the variance in testosterone prescribing at 27% was not accounted for in 
our analysis – so ‘doctor factors’, are likely to be the major determinant. 
This is much lower than in similar analyses where we examined through similar 
regressions links to use of other therapies such as antibiotics or anti depressants where 
r2>0.5 were found (30.31).
All these factors and influences merit further investigation.
Strengths and Weaknesses
A significant strength of this paper is that we have used England national data for 
2018/2019 covering all general practices. A weakness is that the data analysed is at 
general practice level, not individual patient level. Furthermore our study was not 
configured to look for factors beyond those reported in national level databases that may 
associate with the likelihood of a general practice to prescribe testosterone. We did not 
have access to data concerning rates of prostate cancer or polycythaemia. On the former 
point the consensus is that there is no evidence that testosterone treatment in 
hypogonadal man actually causes prostate cancer (32). Also we have not made any 
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We have made a number of assumptions, for example that our modelling of EMAS data 
of the likelihood of an older man being hypogonadal is valid in England in 2018/19, and 
that lower testosterone levels found in men with obesity and diabetes reflect an organic 
process of hypogonadism, rather than being  a physiological epiphenomenon. 
Furthermore the volume of testosterone prescribed at any general practice can be 
affected by dosing frequency. Finally, we were not able here to look at specialist 
recommendations or hospital prescribing.
Conclusions
The level of awareness in the population and family doctors of the importance of 
screening for and treating HG, has significant consequences for both quality of life, longer 
term general health and mortality. If doctors are not prompting older males to consider 
these conditions and so are not detecting and treating the symptomatic patients then it is 
likely that the much higher proportion of less symptomatic patients may go undetected.
The variation in testosterone prescribed at a general practice level is largely related to the 
general practitioner choice and therefore may be amenable to measures to increase 
knowledge and awareness. More consistent prescribing of testosterone in the UK and in 
other health care systems, backed by robust national / international guidance and training 
that is independent of ‘Pharma’, so as to improve the quality of diagnosis, can only serve 
to improve the health prospects of men with hypogonadism at all stages of life.
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Figure 1: Change in the balance of mode of testosterone supplementation prescribed 
between 2011 and 2018.
Figure 2: Variation in numbers pontetially needing treatment for HG and % being 
prescribing of testosterone across general practices in England 2018/19.
Figure 3:  For all the 6741 general practices included in the survey (plotted by estimated 
number of men with hypogonadism), the relation between the actual prescribing of 
testosterone replacement as defined daily dose (DDD) and predicted prevalence of 
hypogonadism at the same general practice. The 95% control limits refer the Funnel Plot 
of the distribution of testosterone prescribing.
Figure 4: Relation between the prescribing of testosterone and phosphodiesterase type 
5 inhibitors (PDE5-i) prescribing in univariate analysis (r2 = 0.95).
Figure 5: General practice level regression for 6741 general practices in England, 
describing the factors linked to the prescribing of testosterone.
Definitions: PRESCR = prescription; PDE5-i = phosphodiesterase type 2–inhibitor; COPD 
= chronic obstructive pulmonary disease; QOF=quality outcomes framework; LOC = 
location; HbA1C = glycosylated haemoglobin; DM = diabetes mellitus; T2DM = type 2 
diabetes mellitus; GPP + general practice survey; PRACT = practice; IDAOPI = Income 
Deprivation Affecting Older People score; HYP = hypertension; STIA = Stroke/Transient 
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SIZE-Male>40 Number of males on the practice list 1969  
Regression Constant Constant from the regression calculation  -0.092 
LOC-%Male>60 % of males on the list who are >60 in in age 44.5% -0.27 
LOC-North South Latitude%  Latitude value for the practice postcode 52.26 4.2x10-3 
LOC-East West Longitude  Longitude value for the practice postcode -1.27 -2.2x10-3 
LOC-Urban/Rural Pop 
Density/sq km  




Deprivation Older People 
2015  
Income Deprivation Affecting Older People 
score for local area of the practice post code 
17.0 -4.9x10-4 
LOC-GPP Survey % BME 
Ethnicity 
Ethnicity given for responders to each practice 
patient survey 
12.1% -0.036 
PRACT-GPP Survey % Overall 
Good Experience 
% responded ‘GOOD’ when asked about 
overall experience in patient survey  
84.5% Not 
significant 
PRACT-GPP Survey LTC % 
Confident 
% who responded confident when asked about 
self management of their long term condition 
(LTC) 
85.3% 0.021 
PRACT-GP workforce FTE 
Gender % male  
% general practitioners who are male in the 
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PRACT-GP workforceHC Age 
<40 Younger  
% general practitioners whose age<40 in the 
workforce data for general practices 
27.3% -0.0099 
PRACT-GP workforceHC Age 
>55 Older 
% general practitioners whose age >55 in the 




Non UK  
% general practitioners whose country of 
qualification (COQ) is not the UK in the 
workforce data for general practices 
16.7% Not 
significant 
HEALTH-QOF% Reg-CHD  % of patients on practice coronary heart 
disease (CHD) register 
3.2% Not 
significant 
HEALTH-QOF% Reg-COPD  % of patients practice chronic obstructive 
pulmonary disease  (COPD) register 
1.9% 0.81 




HEALTH-QOF% Reg-HYP  % of patients who are on the practice 
hypertension (HYP) register 
14.6% -0.17 
HEALTH-QOF% Reg-OB  % of patients on practice obesity = OB register 8.0% Not 
significant 
HEALTH-QOF% Reg-PAD  % of patients on the practice peripheral 
arterial disease (PAD) register 
0.6% Not 
significant 
HEALTH-QOF% Reg-STIA  % of patients on practice stroke / transient 
ischaemic attack (STIA) register 
1.8% -0.98 
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Age>65 
 































770 6,088 425983 141,994 389 £113,074 






















4 10 163 906 2 £7,147 
INJECTED   6624 180,135 247777 8,940,739 24,495 £11,546,867 
Sachet Testosterone Testim 50mg/5g 
Tube 
2313 7,073 220035 220,035 603 £218,180 
  Testogel Sachet 
50mg/g 
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Pump Testosterone Testavan T/Derm 
Gel 20mg/g 
45 79 8350 3,509 10 £2,353 
  Testogel Pump 
16.2mg/g 
4658 75,884 8669321 3,085,823 8,454 £2,845,622 
  Tostran Pump 2% 
(10mg/actuation) 





3 5 250 1,250 3 £1,275 
GEL   6745 255,433 2.2E+07 7,004,775 19,191 £9,531,953 
OVERALL 
TOTAL 
  7142 441,656 2.3E+07 16,087,509 44,075 £21,191,894 
 
Table 2: Total Testosterone Prescribing 2018/19 for general practices in England. Annualised defined daily doses (DDD) and Totals for each 
mode of administration are shown in bold. 
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